News Immatics Announces First Quarter 2023 Financial Results and Business Update by trophic 16 May, 2023
News Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME by trophic 02 May, 2023
News Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration by trophic 02 May, 2023
